Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_provenance.
- NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_assertion description "[Treatment of established and patient-derived pancreatic cancer cell lines with the MEK1/2 inhibitor trametinib (GSK1120212) inhibited proliferation, and addition of the EGFR/HER2 inhibitor lapatinib enhanced the inhibition elicited by trametinib in three of eight cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_provenance.
- NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_assertion evidence source_evidence_literature NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_provenance.
- NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_assertion SIO_000772 23441129 NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_provenance.
- NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_assertion wasDerivedFrom befree-2016 NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_provenance.
- NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_assertion wasGeneratedBy ECO_0000203 NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_provenance.
- befree-2016 importedOn "2016-02-19" NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_provenance.